Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Lisdexamfetamine dimesylate (Elvanse Adult®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. |
|||
|
|||
Medicine details |
|||
| Medicine name | lisdexamfetamine dimesylate (Elvanse Adult®) | ||
| Formulation | 30 mg, 50 mg and 70 mg capsules | ||
| Reference number | 2534 | ||
| Indication | As part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults |
||
| Company | Shire Pharmaceuticals Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 2615 | ||
| NMG meeting date | 22/07/2015 | ||
| AWMSG meeting date | 16/09/2015 | ||
| Ratification by Welsh Government | 09/10/2015 | ||
| Date of issue | 13/10/2015 | ||
| Date of last review | 25/03/2019 | ||